** Drug developer Annovis Bio's ANVS.N shares fall 4.6% to $5.40 premarket
** ANVS files for up to $50 mln "at-the-market" stock sale agreement to be handled by Oppenheimer
** Co plans to use the proceeds for general corporate purposes, including the development of its lead experimental drug buntanetap
** ANVS set to host its year-end investor webcast late Wednesday
** ANVS has 13.8 mln outstanding shares and $78 mln market capitalization - LSEG data
** As of last close, ANVS shares down 69.7% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。